Previous Article | Next Article 
Infection and Immunity, March 1999, p. 1493-1500, Vol. 67, No. 3
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
Probing the Function of Bordetella
bronchiseptica Adenylate Cyclase Toxin by Manipulating Host
Immunity
Eric T.
Harvill,
Peggy A.
Cotter,
Ming Huam
Yuk, and
Jeff F.
Miller*
Department of Microbiology and Immunology,
UCLA School of Medicine, Los Angeles, California 90095-1747
Received 23 October 1998/Returned for modification 19 November
1998/Accepted 9 December 1998
 |
ABSTRACT |
We have examined the role of adenylate cyclase-hemolysin (CyaA) by
constructing an in-frame deletion in the Bordetella
bronchiseptica cyaA structural gene and comparing wild-type and
cyaA deletion strains in natural host infection models.
Both the wild-type strain RB50 and its adenylate cyclase toxin deletion
(
cyaA) derivative efficiently establish persistent
infections in rabbits, rats, and mice following low-dose inoculation.
In contrast, an inoculation protocol that seeds the lower respiratory
tract revealed significant differences in bacterial numbers and in
polymorphonuclear neutrophil recruitment in the lungs from days 5 to 12 postinoculation. We next explored the effects of disarming specific
aspects of the immune system on the relative phenotypes of wild-type
and
cyaA bacteria. SCID, SCID-beige, or
RAG-1
/
mice succumbed to lethal systemic infection
following high- or low-dose intranasal inoculation with the wild-type
strain but not the
cyaA mutant. Mice rendered
neutropenic by treatment with cyclophosphamide or by knockout mutation
in the granulocyte colony-stimulating factor locus were highly
susceptible to lethal infection by either wild-type or
cyaA strains. These results reveal the significant role
played by neutrophils early in B. bronchiseptica infection and by acquired immunity at later time points and suggest that phagocytic cells are a primary in vivo target of the
Bordetella adenylate cyclase toxin.
 |
INTRODUCTION |
Bordetella bronchiseptica
is a broad-host-range, gram-negative bacterium associated with atrophic
rhinitis in swine, bronchopneumonia in dogs, and rhinotracheitis in
rodents (9). B. bronchiseptica naturally infects
laboratory animals, facilitating analysis of the molecular and cellular
determinants involved in respiratory tract colonization in the context
of naturally occurring bacterium-host interactions. Hallmarks of
experimental infection of immunocompetent animals are efficient
establishment, long-term persistence, and the absence of acute or
chronic disease (5, 37). In B. bronchiseptica and
the closely related human pathogens Bordetella pertussis and Bordetella parapertussis, genes encoding virulence and
colonization factors are transcriptionally activated by a signal
transduction system encoded by the bvgAS operon (Fig. 1)
(32, 33). BvgAS-activated gene products on the bacterial
cell surface include the putative adhesins pertactin, filamentous
hemagglutinin, and fimbriae and the serum resistance protein BrkA
(25, 28, 29). BvgAS also induces expression of a type III
secretion apparatus (38) and a potent adenylate cyclase
toxin which profoundly affects phagocytic cells in vitro (8,
15).
The Bordetella adenylate cyclase toxin (CyaA) is a member of
the RTX family of bacterial exotoxins (8, 15).
Palmitoylation of the 177-kDa CyaA protein by the product of
cyaC (Fig. 1) facilitates insertion and transmembrane
delivery of the catalytic domain into target cells (14, 17).
CyaA-catalyzed production of supraphysiologic amounts of cyclic AMP is
stimulated by calmodulin in the eukaryotic cell cytoplasm, an
adaptation that is shared with the edema factor component of anthrax
toxin (22, 30, 36). The B. bronchiseptica CyaA
amino acid sequence is 98% identical to that of B. pertussis (3). Since the initial description of
phagocyte impotence resulting from CyaA activity (4), in
vitro studies have demonstrated numerous toxic effects on phagocytic
cells. These include the inhibition of chemotaxis, phagocytosis,
superoxide generation, and bacterial killing by neutrophils and
induction of apoptosis in macrophages (4, 7, 15, 21).
Determining an in vivo function for CyaA, however, has been more
difficult. Compared to wild-type (wt) B. pertussis, a
cyaA mutant was recovered in lower numbers from the lungs of
mice and induced less macrophage apoptosis and neutrophil infiltration
but persisted for at least as long as the wt strain (10, 12, 19,
20, 34, 35). The conclusion that CyaA is a colonization factor
underscores the limitations of our understanding of the precise in vivo
role(s) of this toxin.
We have examined the interactions between wt and
cyaA B. bronchiseptica strains in immunocompetent and immunocompromised mice. We show that mice with severe defects in either lymphocyte or
neutrophil function are highly sensitive to B. bronchiseptica infection. A B. bronchiseptica strain
with an in-frame deletion in the cyaA structural gene was as
virulent as the wt in neutropenic mice but avirulent in B- and
T-cell-deficient mice. These data support a model in which CyaA targets
one or more aspects of the innate immune response, most likely
involving neutrophils.
 |
MATERIALS AND METHODS |
Strain construction.
p
cyaA was constructed by cloning a
5.5-kb BamHI-BsmI fragment encompassing
cyaA from B. pertussis into our allelic exchange vector (5), digesting it with ApaLI, and
religating it to delete the two consecutive ApaLI fragments
which encode the central 1,580 codons of cyaA. The 766-bp
BamHI-BsmI fragment remaining in p
cyaA contains 67 bp of cyaA promoter sequence, the first 61 codons, the last 65 codons, and 206 bp 3' to the cyaA stop
codon. Delivery of this allele to the chromosome of RB50 (wt) by two
consecutive homologous recombination events resulted in construction of
strain RB58 (
cyaA). Southern hybridization analysis
confirmed that RB58 was constructed as intended (data not shown). In
vitro assays, performed as previously described (16),
confirmed that supernatants from RB50, but not RB58, contained
adenylate cyclase activity. WD3 (
bscN) and 8W1
(
bscN
cyaA) were constructed as in-frame deletions in
bscN in RB50 and RB58, respectively, as previously described
(38). RB54 was similarly constructed as an in-frame deletion
in bvgS as previously described (5).
Animal experiments.
Rabbits were obtained from Charles River
and were inoculated as previously described (5). BALB/c and
C57BL/6 mice and Wistar rats were obtained from B & K Laboratories.
SCID, SCID-beige, and nude mice were from University of California at
Los Angeles facilities. RAG-1
/
, Beige, and granulocyte
colony-stimulating factor (G-CSF)
/
mice were from
Jackson Laboratories. Rats and mice lightly sedated with halothane were
inoculated with a low dose consisting of 500 to 1,000 bacteria in 5 µl of phosphate-buffered saline (PBS), as previously described
(1), except where a high dose is indicated. The high dose
consisted of 0.5 × 106 to 1.0 × 106
bacteria in 50 µl of PBS, sufficient to seed the entire respiratory tract with bacteria. For survival curves, after the progression of
disease became clear, moribund animals were euthanized to prevent unnecessary suffering. For histological examination, lungs and trachea
were excised as a unit. The trachea was cannulated with a blunt-ended
18-gauge needle attached to a syringe. Lungs were carefully filled with
10% formalin and immersed in 10% formalin for 24 h before
paraffin embedding, sectioning, and hematoxylin-and-eosin staining.
Sections were graded by observers blinded to the treatment of the
sample, and the results were confirmed by an independent assessment by
a pathologist consultant. For toxicity studies, BALB/c mice were
administered RB50 (wt) or RB58 (
cyaA) by
intraperitoneal injection. BALB/c mice were made neutropenic by
intraperitoneal injection of 0.25 g of cyclophosphamide per kg of
body weight 4 days prior to inoculation. Blood leukocytes were counted
with a hemocytometer, and blood smears were stained with Diff-Quik (Baxter Scientific Products) and observed microscopically to confirm that neutrophils were reduced by more than 90%. Animals were handled in accordance with institutional guidelines. Statistical significance was determined by an unpaired t test.
Cytotoxicity.
J774 cells were cultured in Dulbecco modified
Eagle medium with 10% fetal bovine serum. Cells were grown to
approximately 80% confluency, and bacteria were added at a
multiplicity of infection (MOI) of 10. After a 5-min centrifugation at
500 × g, the mixture was incubated at 37°C for
4 h. Cytotoxicity was determined by using the Cytotox96 (Promega)
kit according to the manufacturer's protocol. Mean values and standard
errors were compared by the unpaired t test.
 |
RESULTS |
Construction and in vitro analyses of a
cyaA mutant
of B. bronchiseptica.
We constructed a B. bronchiseptica strain with an in-frame, nonpolar deletion in
cyaA (Fig. 1). Deletion of
cyaA was accompanied by the loss of hemolytic and adenylate
cyclase activities (Materials and Methods). B. pertussis
CyaA has previously been reported to be cytotoxic for the
macrophage-like cell line J774 (21). To determine if a
cyaA B. bronchiseptica strain lacks cytotoxicity for
macrophages, we examined the effects of the wt strain RB50, or its
cyaA derivative, RB58, on J774 cells in vitro. Both wt and
cyaA bacteria efficiently kill J774 cells in vitro
within 4 h (Fig. 2). RB54
(
bvg), which does not express any of the BvgAS-regulated virulence factors, is not cytotoxic for J774 cells. These data indicate
that Bvg-regulated factors aside from CyaA are required for macrophage
killing by B. bronchiseptica.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 1.
Genotypes of B. bronchiseptica strains. RB58
contains an in-frame deletion in the cyaA structural gene.
RB54 contains an in-frame deletion in bvgS, resulting in the
loss of expression of virulence-associated genes.
|
|

View larger version (14K):
[in this window]
[in a new window]
|
FIG. 2.
Cytotoxicity of wt and mutant B. bronchiseptica strains for J774 cells. Bacteria were incubated
with J774 cells at an MOI of 10 for 4 h. Cytotoxicity was
determined by the release of lactate dehydrogenase as measured with the
Cytotox96 kit, and the means and standard errors are presented as
percentages of the total lysis by detergent. All strains differ from
one another (P < 0.001), except for the wt and
cyaA strains and the bscN cyaA and
bvg strains.
|
|
We have recently identified a type III secretion system in
B. bronchiseptica and constructed an in-frame deletion in
bscN (
38). BscN is a homolog of YscN which is
postulated to provide
energy via ATP hydrolysis for the secretion of
proteins by the
Yersinia type III system (
38). A
bscN strain is defective in
secretion of multiple
proteins (
38). This mutant is also reduced
in its macrophage
cytotoxicity in vitro compared to RB50 (
P =
0.0002) but
maintains significantly higher levels of cytotoxicity
than does RB54
(
bvgAS) (
P < 0.0001), suggesting that
there is
a type III-independent mechanism of cytotoxicity
(
38) (Fig.
2). To determine if the remaining cytotoxic
activity of the type
III secretion mutant (
bscN) is due
to CyaA, we deleted
cyaA from
this mutant. The resulting
bscN
cyaA double mutant is significantly
reduced in
macrophage cytotoxicity compared to the
bscN strain
(
P = 0.0002) (Fig.
2). The RAW264 macrophage-like cell
line, the
L2 rat lung epithelial cell line, and rat peritoneal
macrophages
all behaved similarly to J774 cells in this assay. These
data
indicate that
B. bronchiseptica has two independent
mechanisms
capable of mediating macrophage cytotoxicity. Under the in
vitro
conditions used here, the type III secretion system mediates more
efficient killing than does
CyaA.
In vivo comparison of wt and
cya strains of B. bronchiseptica.
To determine if CyaA plays a role in the initial
establishment of infection, rats were inoculated with 10 to 20 CFU of
either the wt or
cyaA strains delivered in a 5-µl
droplet to the external nares. On day 8, B. bronchiseptica
was detected in the respiratory tracts of seven of seven animals given
wt and six of seven given
cyaA bacteria. The 50%
infective dose of both strains is therefore less than 20 CFU,
suggesting that CyaA is not required for B. bronchiseptica
to efficiently establish colonization of the nasal cavity.
To more closely monitor the kinetics of growth in the nose, spread to
the trachea, and persistence in both sites, groups of
rats were
inoculated with wt or
cyaA bacteria (500 CFU in a 5-µl
droplet of PBS) and sacrificed on day 14, 26, 40, or 60. All rats
were
colonized in the nasal cavity at all time points (Fig.
3).
On day 15, all rats were colonized in
the trachea, indicating
that CyaA is not required for colonization of
this normally sterile
site. A statistically significant difference
between the wt and
cyaA strains was observed in tracheal
colonization levels on
day 26 (
P < 0.01), but no such
difference was observed at any
other time point (
P 
0.1). Both strains also efficiently infected
the nose and spread
to the lower respiratory tract of rabbits
inoculated by the low-dose
regimen (data not shown). These data
indicate that CyaA is not required
for
B. bronchiseptica to efficiently
colonize the nasal
cavity and spread to the lower respiratory
tracts of two of its natural
mammalian hosts, rats and rabbits.

View larger version (23K):
[in this window]
[in a new window]
|
FIG. 3.
Time course of rat respiratory tract colonization by wt
and cyaA B. bronchiseptica. Wistar rats were inoculated
intranasally with 50 µl of PBS containing 5 × 105
CFU of either RB50 (wt; open circles) or RB58 ( cyaA;
solid circles), and the numbers of bacteria present in the trachea were
determined at the indicated times postinoculation. Each symbol
represents a single animal, bars represent the means, and the dashed
line represents the lower level of detection. Nasal colonization (col.)
was determined by nasal swab and is presented as the number of B. bronchiseptica-colonized animals over the total number of rats.
*, P < 0.01.
|
|
To monitor bacterial colonization of mice over time, we used two
inoculation regimens to examine independent aspects of infection.
Low-dose, low-volume inoculation (a range of doses from 10 to
1,000 CFU
in a 5-µl droplet of PBS) delivered bacteria to only
the nasal cavity
and tested the ability of the inoculum to establish
infection and
spread to the lower respiratory tract. High-dose,
high-volume
inoculation (0.5 × 10
6 to 1 × 10
6
CFU in 50 µl of PBS) of anesthetized mice seeded bacteria throughout
the respiratory tract and tested the ability of the bacteria to
grow
and persist in the normally sterile environment of the lower
respiratory
tract.
To determine if CyaA is required for efficient colonization of mice by
B. bronchiseptica, groups of mice were inoculated with
a
range of doses of wt or
cyaA bacteria. Doses as low as 5 to
10 CFU in a 5-µl droplet were sufficient to colonize the nasal
cavity of four of five BALB/c mice inoculated with the wt strain
and
three of five inoculated with the
cyaA strain. Doses of
100
CFU or more established infection in all mice, and infected mice
remained colonized with either strain for more than 200 days.
wt and
cyaA strains infected C57BL/6 mice with similar
efficiency.
CyaA is therefore not required for efficient establishment
or
persistence of infection in the mouse nasal cavity, a result
consistent
with observations with
rats.
CyaA has been shown elsewhere to be important for the growth of
B. pertussis early after inoculation into the lungs of mice
(
10,
19,
20,
34,
35). To compare the abilities of wt
and
cyaA B. bronchiseptica strains to grow and persist in the
normally sterile environment of the lower respiratory tract,
anesthetized
mice were inoculated by the high-dose, high-volume regimen
and
sacrificed at days 1, 3, 5, 7, 10, 12, 20, 30, and 45 postinoculation
(Fig.
4). Both wt and
cyaA strains grew in the nose to approximately
10
6 organisms by day 5 and slowly decreased to
10
4 to 10
5 by day 45, remaining at these levels
for the lives of the animals.
Both strains were ultimately cleared from
the trachea and lungs
of mice by day 45. The two strains differed
significantly (
P
0.01) only in the trachea and
lungs, sites of immune surveillance,
on days 5, 7, 10, and 12. These
data indicate that in this high-dose-inoculation
mouse model, CyaA is
required early after inoculation for maximal
growth of
B. bronchiseptica in the trachea and lungs.

View larger version (18K):
[in this window]
[in a new window]
|
FIG. 4.
Time course of mouse respiratory tract colonization by
wt and cyaA B. bronchiseptica. Groups of three female,
4-week-old, BALB/c mice were inoculated intranasally with 50 µl of
PBS containing 5 × 105 CFU of either RB50 (wt; open
circles) or RB58 ( cyaA; solid circles), and the numbers
of CFU present in the nasal cavity, trachea, and lungs were determined
at the indicated times postinoculation. *, P < 0.01.
**, P < 0.001.
|
|
CyaA contributes to neutrophil infiltration and lung
pathology.
In parallel with the time course of Fig. 4, mice were
sacrificed for histological examination of trachea and lungs on days 1, 3, 5, 7, and 10. On day 3, lungs infected with the wt strain showed
extensive exudate from blood vessels and accumulation of cells,
primarily neutrophils, within alveolar spaces (Fig.
5B, panel 1). Inflammatory cell
recruitment continued, filling alveoli in large regions of the lungs by
day 7 (Fig. 5B, panel 3). In contrast, lungs infected with the
cyaA strain showed only a small amount of infiltration or
pathology at days 1 and 3 and very little thereafter (Fig. 5B, panels 2 and 4). On day 3 postinoculation, bronchoalveolar lavage recovered
(6.5 ± 1.1) × 106 neutrophils from lungs infected
with the wt strain, significantly more than the (3.9 ± 0.8) × 105 neutrophils from lungs infected with the
cyaA strain (P = 0.0002). Histological
sections were examined in a blinded fashion and graded for pathology.
Lungs of mice infected with the wt strain had consistently greater
pathology scores, based on the extent of immune cell infiltration, tissue damage, consolidation, and necrosis (Fig. 5A). Lungs infected with the
cyaA strain showed only minor diffuse
infiltration with little tissue damage and no consolidated or necrotic
regions. These data indicate that, following high-dose, high-volume
inoculation, the presence of CyaA results in increased pulmonary
neutrophil infiltration and damage.


View larger version (185K):
[in this window]
[in a new window]
|
FIG. 5.
Mouse lung pathology induced by wt and cyaA B. bronchiseptica. BALB/c mice were inoculated in parallel with those
for Fig. 3. Histological sections of lung tissues were prepared as
described in Materials and Methods. (A) Samples were submitted for
observation in a blinded fashion. Upon examination, samples were given
scores of 0 (no pathology), 1 (mild inflammation in 10% of the
bronchioles and/or 10% of lung tissue), 2 (inflammation in 10 to
30% of bronchioles and/or mild inflammation in 10 to 30% of lung
tissue), 3 (inflammation in >30% of bronchioles and mild to moderate
inflammation in >30% of lung tissue), and 4 (inflammation in >50%
of bronchioles and moderate to severe inflammation in >30% of lung
tissue). Bars indicate the averages of five animals. Open circles
represent animals infected with RB50 (wt), and solid circles represent
animals infected with RB58 ( cyaA). (B) Representative
sections of lungs infected with wt (panels 1 and 3) or
cyaA (panels 2 and 4) bacteria on day 3 (panels 1 and 2)
or day 7 (panels 3 and 4). Magnification, ×100 (panels 1 to 4) and
×1,000 (panels 5 and 6).
|
|
CyaA is required for virulence in SCID-Beige mice.
We next
explored the effect of disarming one or more aspects of the host immune
response on the phenotype of CyaA in vivo. Cytotoxicity assays
indicated that CyaA can kill phagocytic cells, and in vivo data
identified a role for CyaA early after infection when phagocytes are a
prominent aspect of innate immunity. To focus on interactions with the
innate immune system, SCID-beige mice (BALB/c genetic background),
which are deficient in T and B cells as well as NK cell activities
(6, 31), were inoculated intranasally with either wt or
cyaA bacteria (Fig. 6A).
Both groups of mice were healthy for about 30 days, after which animals infected with wt bacteria began to display signs of illness such as
piloerection, weight loss, hunched stature, listlessness, and eventually loss of responsiveness followed by death. In striking contrast to the 100% lethality observed with the wt strain, mice infected with the
cyaA strain displayed no symptoms of
disease and were healthy for more than 200 days. This dichotomy was
observed following low-dose, low-volume or high-dose, high-volume
intranasal inoculation. The beige mutation has pleiotropic effects
which include defects in macrophage and neutrophil functions
(2). However, the wt strain, but not the
cyaA
strain, also established similarly lethal infections in SCID (both
BALB/c and C3H backgrounds) and RAG-1
/
(C57BL/6
background) mice. Addition of the beige mutation to the SCID allele
decreased the average time to death, but in animals carrying the beige
mutation alone (C57BL/6 background), no lethality was observed (data
not shown). Together, these data indicate that T cells and B cells are
required to prevent killing by B. bronchiseptica. As
expected, RB54 (
bvgS) did not kill or colonize SCID-beige mice, indicating that Bvg-activated virulence factors are required for
colonization of these animals.



View larger version (161K):
[in this window]
[in a new window]
|
FIG. 6.
Infection of SCID-Beige mice with wt and cyaA
B. bronchiseptica. (A) Four-week-old SCID-Beige mice were
inoculated with B. bronchiseptica, and percent survival over
time is shown. Open symbols represent groups of eight animals
inoculated with 103 CFU of either RB50 (wt; circles) or
RB58 ( cyaA; diamonds) delivered in a 5-µl droplet to
the external nares. Solid symbols represent groups of four mice
inoculated with 5 × 105 CFU of either RB50 (wt;
circles) or RB58 ( cyaA; diamonds) delivered in a 50-µl
volume to the respiratory tract via the nares. (B) Colonization of
various tissues by wt and cyaA B. bronchiseptica. Groups
of three 4-week-old, female, SCID-Beige mice were inoculated with 1,000 CFU of either RB50 (wt; open bars) or RB58 ( cyaA; hatched
bars) delivered in a 5-µl droplet to the external nares. Mice were
sacrificed at 45 days postinoculation, and colonization levels in the
nasal cavity, trachea, lungs, liver, and spleen were determined. Mean
log10 CFU per organ or tissue section ± 1 standard
error are shown. The dashed line represents the lower limit of
detection. *, P < 0.01. **, P < 0.001. (C) Representative sections of SCID-Beige mouse lungs
infected with wt (panels 1 and 3) or cyaA (panels 2 and
4) bacteria on day 3 (panels 1 and 2) or day 7 (panels 3 and 4).
Magnification, ×100.
|
|
SCID-beige mice inoculated with the wt strain by the low-dose,
low-volume regimen were moribund at approximately day 45, but
those
inoculated with the
cyaA strain remained healthy. We
determined
the relative distribution of bacteria at this time point
with
SCID-beige mice inoculated by the low-dose, low-volume regimen.
Colonization levels in various organs were determined 45 days
after
inoculation. At this time, the wt strain was recovered in
high numbers
in the nasal cavity, trachea, and lungs as well as
other organs
including liver and spleen, indicating that the infection
had escaped
the respiratory tract and had spread systemically
(Fig.
6B). The
cyaA strain was recovered from the nasal cavity
and
trachea at 100- to 1,000-fold-lower numbers than was the wt
strain and
was not detected in the lungs or at systemic sites
(
P < 0.01 at all
sites).
Histological examination of the lungs of SCID-beige mice 3 and 7 days
after high-dose, high-volume inoculation revealed that
the wt strain
produced lung pathology even more severe than that
of BALB/c mice at
this time point (Fig.
6C, panels 1 and 3). The
cyaA
strain, however, produced very little lung pathology at
day 3, 7, or 45 postinoculation (Fig.
6C, panels 2 and 4, and
data not shown).
Together, these results show that CyaA is critical
to the ability of
B. bronchiseptica to cause systemic infections
in B- and
T-cell-deficient mice, indicating that its target is
among the innate
immune mechanisms retained by these
animals.
Both wt and
cyaA strains are highly virulent in
neutropenic mice.
Prominent among the defenses present in
lymphocyte-deficient mice are polymorphonuclear neutrophils. If
neutrophils are a primary target for CyaA, then mice depleted of
neutrophils should be equally susceptible to infection with wt or with
cyaA B. bronchiseptica. BALB/c mice were rendered
neutropenic by treatment with cyclophosphamide, which reduced their
blood neutrophil count by >90%. These mice were rapidly killed by
high-dose, high-volume inoculation with the wt strain (Fig.
7A), suggesting that neutrophils play a
critical role in the early response to B. bronchiseptica
infection. These mice were also rapidly killed by the
cyaA strain delivered by the same high-dose, high-volume
regimen that caused minimal pathology in normal or SCID-beige mice,
indicating that CyaA is not required for B. bronchiseptica
killing of neutropenic mice. RB54 (
bvg) did not kill
cyclophosphamide-treated mice, indicating a requirement for
Bvg-activated factors other than CyaA. As cyclophosphamide has
pleiotropic effects, we used an additional source of
neutrophil-deficient animals. G-CSF
/
mice (B6,129
genetic background) lack both genomic copies of the G-CSF gene and have
reduced numbers of neutrophils and impaired neutrophil mobilization
(23). These animals also quickly succumbed to infection by
wt or
cyaA, but not RB54 (
bvg), bacteria
(Fig. 7B). Removing neutrophils, therefore, eliminated the in vivo
phenotype of CyaA.

View larger version (15K):
[in this window]
[in a new window]
|
FIG. 7.
Comparison of wt and cyaA B. bronchiseptica infections of neutropenic mice. Groups of four
BALB/c mice rendered neutropenic by cyclophosphamide treatment (A) or
G-CSF / mice (B) were inoculated with 5 × 105 CFU of either RB50 (wt; open circles), RB58
( cyaA; open diamonds), RB54 ( bvgS; solid
circles), or PBS (open squares) delivered in a 50-µl volume. The
percentages of animals (n = 4) surviving over time are
indicated.
|
|
 |
DISCUSSION |
Both B. pertussis (20) and B. bronchiseptica (this work)
cyaA mutants lack
hemolytic and adenylate cyclase activities. The B. pertussis
cyaA mutant is also deficient in macrophage cytotoxicity
(21); however, the effect of B. bronchiseptica CyaA on macrophages is apparent only when the type III secretion system
is disrupted (38) (Fig. 2). The remaining cytotoxicity displayed by the type III mutant (
bscN) is attributable
to CyaA, as the double mutant (
bscN
cyaA) has no
detectable cytotoxicity. The level of cytotoxic activity attributable
to B. bronchiseptica CyaA 4 h after infection at an MOI
of 10 is in rough agreement with a previous report of B. pertussis CyaA-mediated cytotoxicity, which required 8 h of
infection with B. pertussis at an MOI of 100 to achieve
100% death (21). wt B. bronchiseptica, with an intact type III secretion system, kills 100% of macrophages in as
little at 2 h at an MOI of 10 (data not shown). The type III secretion system is dramatically more efficient than CyaA in this respect. In vitro experiments, however, do not necessarily indicate in
vivo functions.
In vivo experiments using the low-dose, low-volume inoculation regimen
highlight several advantages of the B. bronchiseptica animal
model. B. pertussis, which is highly contagious in humans (18), must be delivered in high doses throughout the
respiratory tract to establish even a transient infection in mice. It
is therefore difficult to extrapolate results obtained with the mouse
model to the events that occur during B. pertussis infection
of its human host, especially those that occur during initial
colonization. The low-dose, low-volume B. bronchiseptica
model, on the other hand, rigorously tests the ability of small numbers
of bacteria to colonize and grow in the nasal cavity and to spread to
the lower respiratory tract. In these assays, CyaA is not required for
efficient colonization of the nasal cavity or spread to the trachea,
although it may be required for persistence at high levels in the
trachea. Although CyaA is not required for colonization, these data
suggest that it may be involved in modulating the immune response.
High-dose, high-volume inoculation overcomes the cleansing effect of
the mucociliary escalator of the trachea and deposits bacteria deep in
the lungs, where debris is less efficiently washed away. Growth within
lung alveoli may be less dependent on adhesins involved in attachment
to ciliated epithelia and more dependent on toxins and factors that
affect the immune response in this normally sterile site. It has
previously been shown that in this environment CyaA is critical for the
growth of B. pertussis and is involved in neutrophil
recruitment and phagocyte apoptosis (10-12, 19, 20, 26, 34,
35). A human B. bronchiseptica isolate with an
uncharacterized defect in hemolysin expression was previously compared
with a hemolytic human isolate (13). Although a difference
in mouse lung colonization was observed, the defect could not be
definitively attributed to CyaA.
Determining the role of individual bacterial virulence factors, or
specific immune mechanisms, in a complex bacterium-host relationship
can be difficult. The classic approach of deleting a single bacterial
virulence factor, or a single aspect of host immunity, may reveal the
importance of that factor or immune mechanism by throwing the entire
interaction out of balance. However, persistent bacterial infections
can be carefully balanced, multifactorial, dynamic relationships in
which any change on one side may be compensated for by numerous
buffering factors on either side. In this context, ablation of a
bacterial virulence factor, even a relatively important one, may not
result in a perceptible difference in the course of infection. This
approach may reveal that a factor is required for infection but seldom
provides insight into the mechanisms involved. An alternative tactic is
to combine the tools of bacterial and mammalian genetics to alter both
sides of the interaction. The advantages of this strategy are twofold.
First, disarming the host immune system can destabilize the
interaction, allowing differences between wt and mutant bacteria to be
more easily identified. Second, by creation of a defect on one side and
then identification of a compensatory defect on the other, bacterial
virulence factors can be matched to specific immune responses that they
affect in vivo. Here we use isogenic wt and
cyaA strains
in combination with mice with defined immune system defects to identify
interactions between CyaA and subsets of the host immune system.
As summarized in Fig. 8, we observed
three distinct relationships between the presence or absence of a
functional cyaA locus and the outcome of B. bronchiseptica infection. In immunocompetent animals, or animals
carrying the beige mutation alone, the summation of host defenses
limits infection by wt or
cyaA bacteria (Fig. 8A)
(24, 27). In contrast, decreased lymphocyte function in RAG-1
/
, SCID, or SCID-beige mice creates a situation
where the absence or presence of CyaA determines whether the animal
lives or dies (Fig. 8B). Presumably, CyaA is active against
immunological defenses that are retained in SCID-beige mice and are
able to control infection by the mutant strain, but not by the
toxin-expressing wt strain. Neutrophils are prominent immune effector
cells that are present and active in these immunocompromised animals.
Addition of the beige mutation to the SCID background decreases the
time to death, an effect that may result from the lack of NK-mediated
activation of phagocytic cells or from inherent phagocyte defects
associated with the beige allele (2). If the adenylate
cyclase toxin does indeed target phagocytic cells, then eliminating the
target should eliminate the phenotype associated with the toxin.
Induction of neutropenia with cyclophosphamide, or by knockout mutation
in the G-CSF locus, results in identical, lethal infections by wt and
by
cyaA bacteria (Fig. 8C), indicating that neutrophils
are critical to the early defense against B. bronchiseptica
infection and that removing neutrophils eliminates the phenotype of
CyaA. In normal and SCID-beige mice, the
cya strain is
more efficiently contained with less neutrophil infiltration and
pathology than is wt B. bronchiseptica, supporting a model
in which CyaA inhibits neutrophil-mediated antibacterial effects.
Although this model implicates neutrophils, it does not require that
they be the only, or even the primary, target of the toxin. For
example, neutrophil activities could be modulated through an
intermediary such as macrophages, NK cells, or epithelial cells via
immunomodulatory signals. However, it is clear from our results that
CyaA targets one or more functions associated with innate immunity and
that depletion of neutrophils removes the requirement for CyaA in
lethal B. bronchiseptica infection.

View larger version (30K):
[in this window]
[in a new window]
|
FIG. 8.
Model of the role of CyaA in infection of
immunocompetent (A), T- and B-cell-deficient (B), and neutropenic (C)
mice. See the text for description.
|
|
Mice with specific immune system defects have been used to reveal which
aspects of immunity are most important in resisting particular
pathogens. Likewise, the use of bacterial mutants with wt animals can
sometimes reveal the importance of individual bacterial virulence
factors during infection. Although results from these types of analyses
may indicate that a specific virulence factor or immune effector
function is important, they do not provide information about the
mechanisms or specific interactions involved. By combining these two
approaches, we have been able to implicate an interaction between a
bacterial virulence factor and immune effector cells in vivo.
 |
ACKNOWLEDGMENTS |
This work was supported by NIH grant AI38417 (to J.F.M.) and USDA
grant 96-35204-3827 (to E.T.H.), and M.H.Y. was supported by a
postdoctoral fellowship from the Damon Runyon-Walter Winchell Foundation.
We gratefully acknowledge Nora Rozengurt for consultation on mouse lung pathology.
 |
FOOTNOTES |
*
Corresponding author. Mailing address: Department of
Microbiology and Immunology, UCLA School of Medicine, Center for the Health Sciences, 10833 LeConte Ave., Los Angeles, CA 90095-1747. Phone:
(310) 206-7926. Fax: (310) 206-3865. E-mail:
jfmiller{at}ucla.edu.
Editor:
P. E. Orndorff
 |
REFERENCES |
| 1.
|
Akerley, B. J.,
P. A. Cotter, and J. F. Miller.
1995.
Ectopic expression of the flagellar regulon alters development of the Bordetella-host interaction.
Cell
80:611-620[Medline].
|
| 2.
|
Appelberg, R.,
A. G. Castro,
S. Gomes,
J. Pedrosa, and M. T. Silva.
1995.
Susceptibility of beige mice to Mycobacterium avium: role of neutrophils.
Infect. Immun.
63:3381-3387[Abstract].
|
| 3.
|
Betsou, F.,
O. Sismeiro,
A. Danchin, and N. Guiso.
1995.
Cloning and sequence of the Bordetella bronchiseptica adenylate cyclase-hemolysin-encoding gene: comparison with the Bordetella pertussis gene.
Gene
162:165-166[Medline].
|
| 4.
|
Confer, D. L., and J. W. Eaton.
1982.
Phagocyte impotence caused by an invasive bacterial adenylate cyclase.
Science
217:948-950[Abstract/Free Full Text].
|
| 5.
|
Cotter, P. A., and J. F. Miller.
1994.
BvgAS-mediated signal transduction: analysis of phase-locked regulatory mutants of Bordetella bronchiseptica in a rabbit model.
Infect. Immun.
62:3381-3390[Abstract/Free Full Text].
|
| 6.
|
Dorshkind, K.,
G. M. Keller,
R. A. Phillips,
R. G. Miller,
G. C. Bosma,
M. O'Toole, and M. J. Bosma.
1984.
Functional status of cells from lymphoid and myeloid tissues in mice with severe combined immunodeficiency disease.
J. Immunol.
132:1804-1808[Abstract].
|
| 7.
|
Friedman, R. L.,
R. L. Fiederlein,
L. Glasser, and J. N. Galgiani.
1987.
Bordetella pertussis adenylate cyclase: effects of affinity-purified adenylate cyclase on human polymorphonuclear leukocyte functions.
Infect. Immun.
55:135-140[Abstract/Free Full Text].
|
| 8.
|
Glaser, P.,
D. Ladant,
O. Sezer,
F. Pichot,
A. Ullmann, and A. Danchin.
1988.
The calmodulin-sensitive adenylate cyclase of Bordetella pertussis: cloning and expression in Escherichia coli.
Mol. Microbiol.
2:19-30[Medline].
|
| 9.
|
Goodnow, R. A.
1980.
Biology of Bordetella bronchiseptica.
Microbiol. Rev.
44:722-738[Free Full Text].
|
| 10.
|
Goodwin, M. S., and A. A. Weiss.
1990.
Adenylate cyclase toxin is critical for colonization and pertussis toxin is critical for lethal infection by Bordetella pertussis in infant mice.
Infect. Immun.
58:3445-3447[Abstract/Free Full Text].
|
| 11.
|
Gross, M. K.,
D. C. Au,
A. L. Smith, and D. R. Storm.
1992.
Targeted mutations that ablate either the adenylate cyclase or hemolysin function of the bifunctional cyaA toxin of Bordetella pertussis abolish virulence.
Proc. Natl. Acad. Sci. USA
89:4898-4902[Abstract/Free Full Text].
|
| 12.
|
Gueirard, P.,
A. Druilhe,
M. Pretolani, and N. Guiso.
1998.
Role of adenylate cyclase-hemolysin in alveolar macrophage apoptosis during Bordetella pertussis infection in vivo.
Infect. Immun.
66:1718-1725[Abstract/Free Full Text].
|
| 13.
|
Gueirard, P.,
P. Minoprio, and N. Guiso.
1996.
Intranasal inoculation of Bordetella bronchiseptica in mice induces long-lasting antibody and T-cell mediated immune responses.
Scand. J. Immunol.
43:181-192[Medline].
|
| 14.
|
Hackett, M.,
L. Guo,
J. Shabanowitz,
D. F. Hunt, and E. L. Hewlett.
1994.
Internal lysine palmitoylation in adenylate cyclase toxin from Bordetella pertussis.
Science
266:433-435[Abstract/Free Full Text].
|
| 15.
|
Hanski, E.
1989.
Invasive adenylate cyclase toxin of Bordetella pertussis.
Trends Biochem. Sci.
14:459-463[Medline].
|
| 16.
|
Hewlett, E., and J. Wolff.
1976.
Soluble adenylate cyclase from the culture medium of Bordetella pertussis: purification and characterization.
J. Bacteriol.
127:890-898[Abstract/Free Full Text].
|
| 17.
|
Hewlett, E. L.,
M. C. Gray,
I. E. Ehrmann,
N. J. Maloney,
A. S. Otero,
L. Gray,
M. Allietta,
G. Szabo,
A. A. Weiss, and E. M. Barry.
1993.
Characterization of adenylate cyclase toxin from a mutant of Bordetella pertussis defective in the activator gene, cyaC.
J. Biol. Chem.
268:7842-7848[Abstract/Free Full Text].
|
| 18.
|
Kendrick, P. L.
1940.
Secondary familial attack rates from pertussis in vaccinated and unvaccinated children.
Am. J. Hyg.
32:89-91.
|
| 19.
|
Khelef, N.,
C. M. Bachelet,
B. B. Vargaftig, and N. Guiso.
1994.
Characterization of murine lung inflammation after infection with parental Bordetella pertussis and mutants deficient in adhesins or toxins.
Infect. Immun.
62:2893-2900[Abstract/Free Full Text]. (Erratum, 62:5707.)
|
| 20.
|
Khelef, N.,
H. Sakamoto, and N. Guiso.
1992.
Both adenylate cyclase and hemolytic activities are required by Bordetella pertussis to initiate infection.
Microb. Pathog.
12:227-235[Medline].
|
| 21.
|
Khelef, N.,
A. Zychlinsky, and N. Guiso.
1993.
Bordetella pertussis induces apoptosis in macrophages: role of adenylate cyclase-hemolysin.
Infect. Immun.
61:4064-4071[Abstract/Free Full Text].
|
| 22.
|
Leppla, S. H.
1982.
Anthrax toxin edema factor: a bacterial adenylate cyclase that increases cyclic AMP concentrations of eukaryotic cells.
Proc. Natl. Acad. Sci. USA
79:3162-3166[Abstract/Free Full Text].
|
| 23.
|
Lieschke, G. J.,
D. Grail,
G. Hodgson,
D. Metcalf,
E. Stanley,
C. Cheers,
K. J. Fowler,
S. Basu,
Y. F. Zhan, and A. R. Dunn.
1994.
Mice lacking granulocyte colony-stimulating factor have chronic neutropenia, granulocyte and macrophage progenitor cell deficiency, and impaired neutrophil mobilization.
Blood
84:1737-1746[Abstract/Free Full Text].
|
| 24.
|
Mills, K. H.,
A. Barnard,
J. Watkins, and K. Redhead.
1993.
Cell-mediated immunity to Bordetella pertussis: role of Th1 cells in bacterial clearance in a murine respiratory infection model.
Infect. Immun.
61:399-410[Abstract/Free Full Text].
|
| 25.
|
Mooi, F. R.,
W. H. Jansen,
H. Brunings,
H. Gielen,
H. G. J. van der Heide,
H. C. Walvoort, and P. A. M. Guinee.
1992.
Construction and analysis of Bordetella pertussis mutants defective in the production of fimbriae.
Microb. Pathog.
12:127-135[Medline].
|
| 26.
|
Oldenburg, D. J.,
M. K. Gross,
A. L. Smith, and D. R. Storm.
1993.
Virulence of a Bordetella pertussis strain expressing a mutant adenylyl cyclase with decreased calmodulin affinity.
Microb. Pathog.
14:489-493[Medline].
|
| 27.
|
Redhead, K.,
J. Watkins,
A. Barnard, and K. H. Mills.
1993.
Effective immunization against Bordetella pertussis respiratory infection in mice is dependent on induction of cell-mediated immunity.
Infect. Immun.
61:3190-3198[Abstract/Free Full Text].
|
| 28.
|
Relman, D. A.,
M. Domenighini,
E. I. Tuomanen,
R. Rappuoli, and S. Falkow.
1989.
Filamentous hemagglutinin of Bordetella pertussis: nucleotide sequence and crucial role in adherence.
Proc. Natl. Acad. Sci. USA
86:2634-2641.
|
| 29.
|
Roberts, M.,
I. Cropley,
S. Chatfield, and G. Dougan.
1993.
Protection of mice against respiratory Bordetella pertussis infection by intranasal immunization with P.69 and FHA.
Vaccine
11:866-872[Medline].
|
| 30.
|
Robertson, D. L.,
M. T. Tippetts, and S. H. Leppla.
1988.
Nucleotide sequence of the Bacillus anthracis edema factor gene (cya): a calmodulin-dependent adenylate cyclase.
Gene
73:363-371[Medline].
|
| 31.
|
Roder, J., and A. Duwe.
1979.
The beige mutation in the mouse selectively impairs natural killer cell function.
Nature
278:451-453[Medline].
|
| 32.
|
Uhl, M. A., and J. F. Miller.
1996.
Central role of the BvgS receiver as a phosphorylated intermediate in a complex two-component phosphorelay.
J. Biol. Chem.
271:33176-33180[Abstract/Free Full Text].
|
| 33.
|
Uhl, M. A., and J. F. Miller.
1996.
Integration of multiple domains in a two-component sensor protein: the Bordetella pertussis BvgAS phosphorelay.
EMBO J.
15:1028-1036[Medline].
|
| 34.
|
Weiss, A. A., and M. S. Goodwin.
1989.
Lethal infection by Bordetella pertussis mutants in the infant mouse model.
Infect. Immun.
57:3757-3764[Abstract/Free Full Text].
|
| 35.
|
Weiss, A. A.,
E. L. Hewlett,
G. A. Myers, and S. Falkow.
1984.
Pertussis toxin and extracytoplasmic adenylate cyclase as virulence factors of Bordetella pertussis.
J. Infect. Dis.
150:219-222[Medline].
|
| 36.
|
Wolff, J.,
G. H. Cook,
A. R. Goldhammer, and S. A. Berkowitz.
1980.
Calmodulin activates prokaryotic adenylate cyclase.
Proc. Natl. Acad. Sci. USA
77:3841-3844[Abstract/Free Full Text].
|
| 37.
|
Yoda, H.,
K. Nakayama, and M. Nakagawa.
1982.
Experimental infection of Bordetella bronchiseptica to rabbits.
Exp. Anim.
31:113-118.
|
| 38.
|
Yuk, M. H.,
E. T. Harvill, and J. F. Miller.
1998.
The bvgAS virulence control system regulates type III secretion in Bordetella bronchiseptica.
Mol. Microbiol.
28:945-959[Medline].
|
Infection and Immunity, March 1999, p. 1493-1500, Vol. 67, No. 3
0019-9567/99/$04.00+0
Copyright © 1999, American Society for Microbiology. All rights reserved.
This article has been cited by other articles:
-
Buboltz, A. M., Nicholson, T. L., Weyrich, L. S., Harvill, E. T.
(2009). Role of the Type III Secretion System in a Hypervirulent Lineage of Bordetella bronchiseptica. Infect. Immun.
77: 3969-3977
[Abstract]
[Full Text]
-
Nicholson, T. L., Brockmeier, S. L., Loving, C. L.
(2009). Contribution of Bordetella bronchiseptica Filamentous Hemagglutinin and Pertactin to Respiratory Disease in Swine. Infect. Immun.
77: 2136-2146
[Abstract]
[Full Text]
-
Andreasen, C., Carbonetti, N. H.
(2009). Role of Neutrophils in Response to Bordetella pertussis Infection in Mice. Infect. Immun.
77: 1182-1188
[Abstract]
[Full Text]
-
Buboltz, A. M., Nicholson, T. L., Parette, M. R., Hester, S. E., Parkhill, J., Harvill, E. T.
(2008). Replacement of Adenylate Cyclase Toxin in a Lineage of Bordetella bronchiseptica. J. Bacteriol.
190: 5502-5511
[Abstract]
[Full Text]
-
Williams, C. L., Haines, R., Cotter, P. A.
(2008). Serendipitous Discovery of an Immunoglobulin-Binding Autotransporter in Bordetella Species. Infect. Immun.
76: 2966-2977
[Abstract]
[Full Text]
-
Goebel, E. M., Wolfe, D. N., Elder, K., Stibitz, S., Harvill, E. T.
(2008). O Antigen Protects Bordetella parapertussis from Complement. Infect. Immun.
76: 1774-1780
[Abstract]
[Full Text]
-
Mann, P., Goebel, E., Barbarich, J., Pilione, M., Kennett, M., Harvill, E.
(2007). Use of a Genetically Defined Double Mutant Strain of Bordetella bronchiseptica Lacking Adenylate Cyclase and Type III Secretion as a Live Vaccine. Infect. Immun.
75: 3665-3672
[Abstract]
[Full Text]
-
Basler, M., Knapp, O., Masin, J., Fiser, R., Maier, E., Benz, R., Sebo, P., Osicka, R.
(2007). Segments Crucial for Membrane Translocation and Pore-forming Activity of Bordetella Adenylate Cyclase Toxin. J. Biol. Chem.
282: 12419-12429
[Abstract]
[Full Text]
-
Fiser, R., Masin, J., Basler, M., Krusek, J., Spulakova, V., Konopasek, I., Sebo, P.
(2007). Third Activity of Bordetella Adenylate Cyclase (AC) Toxin-Hemolysin: MEMBRANE TRANSLOCATION OF AC DOMAIN POLYPEPTIDE PROMOTES CALCIUM INFLUX INTO CD11b+ MONOCYTES INDEPENDENTLY OF THE CATALYTIC AND HEMOLYTIC ACTIVITIES. J. Biol. Chem.
282: 2808-2820
[Abstract]
[Full Text]
-
Siciliano, N. A., Skinner, J. A., Yuk, M. H.
(2006). Bordetella bronchiseptica Modulates Macrophage Phenotype Leading to the Inhibition of CD4+ T Cell Proliferation and the Initiation of a Th17 Immune Response. J. Immunol.
177: 7131-7138
[Abstract]
[Full Text]
-
Irie, Y., Preston, A., Yuk, M. H.
(2006). Expression of the Primary Carbohydrate Component of the Bordetella bronchiseptica Biofilm Matrix Is Dependent on Growth Phase but Independent of Bvg Regulation.. J. Bacteriol.
188: 6680-6687
[Abstract]
[Full Text]
-
Inatsuka, C. S., Julio, S. M., Cotter, P. A.
(2005). Bordetella filamentous hemagglutinin plays a critical role in immunomodulation, suggesting a mechanism for host specificity. Proc. Natl. Acad. Sci. USA
102: 18578-18583
[Abstract]
[Full Text]
-
Zeng, X., Moore, T. A., Newstead, M. W., Deng, J. C., Kunkel, S. L., Luster, A. D., Standiford, T. J.
(2005). Interferon-Inducible Protein 10, but Not Monokine Induced by Gamma Interferon, Promotes Protective Type 1 Immunity in Murine Klebsiella pneumoniae Pneumonia. Infect. Immun.
73: 8226-8236
[Abstract]
[Full Text]
-
Kostina, E., Ofek, I., Crouch, E., Friedman, R., Sirota, L., Klinger, G., Sahly, H., Keisari, Y.
(2005). Noncapsulated Klebsiella pneumoniae Bearing Mannose-Containing O Antigens Is Rapidly Eradicated from Mouse Lung and Triggers Cytokine Production by Macrophages following Opsonization with Surfactant Protein D. Infect. Immun.
73: 8282-8290
[Abstract]
[Full Text]
-
Julio, S. M., Cotter, P. A.
(2005). Characterization of the Filamentous Hemagglutinin-Like Protein FhaS in Bordetella bronchiseptica. Infect. Immun.
73: 4960-4971
[Abstract]
[Full Text]
-
Edwards, J. A., Groathouse, N. A., Boitano, S.
(2005). Bordetella bronchiseptica Adherence to Cilia Is Mediated by Multiple Adhesin Factors and Blocked by Surfactant Protein A. Infect. Immun.
73: 3618-3626
[Abstract]
[Full Text]
-
Carbonetti, N. H., Artamonova, G. V., Andreasen, C., Bushar, N.
(2005). Pertussis Toxin and Adenylate Cyclase Toxin Provide a One-Two Punch for Establishment of Bordetella pertussis Infection of the Respiratory Tract. Infect. Immun.
73: 2698-2703
[Abstract]
[Full Text]
-
Mattoo, S., Cherry, J. D.
(2005). Molecular Pathogenesis, Epidemiology, and Clinical Manifestations of Respiratory Infections Due to Bordetella pertussis and Other Bordetella Subspecies. Clin. Microbiol. Rev.
18: 326-382
[Abstract]
[Full Text]
-
Reissinger, A., Skinner, J. A., Yuk, M. H.
(2005). Downregulation of Mitogen-Activated Protein Kinases by the Bordetella bronchiseptica Type III Secretion System Leads to Attenuated Nonclassical Macrophage Activation. Infect. Immun.
73: 308-316
[Abstract]
[Full Text]
-
Widney, D. P., Hu, Y., Foreman-Wykert, A. K., Bui, K. C., Nguyen, T. T., Lu, B., Gerard, C., Miller, J. F., Smith, J. B.
(2005). CXCR3 and Its Ligands Participate in the Host Response to Bordetella bronchiseptica Infection of the Mouse Respiratory Tract but Are Not Required for Clearance of Bacteria from the Lung. Infect. Immun.
73: 485-493
[Abstract]
[Full Text]
-
Irie, Y., Mattoo, S., Yuk, M. H.
(2004). The Bvg Virulence Control System Regulates Biofilm Formation in Bordetella bronchiseptica. J. Bacteriol.
186: 5692-5698
[Abstract]
[Full Text]
-
Skinner, J. A., Reissinger, A., Shen, H., Yuk, M. H.
(2004). Bordetella Type III Secretion and Adenylate Cyclase Toxin Synergize to Drive Dendritic Cells into a Semimature State. J. Immunol.
173: 1934-1940
[Abstract]
[Full Text]
-
Vougier, S., Mary, J., Dautin, N., Vinh, J., Friguet, B., Ladant, D.
(2004). Essential Role of Methionine Residues in Calmodulin Binding to Bordetella pertussis Adenylate Cyclase, as Probed by Selective Oxidation and Repair by the Peptide Methionine Sulfoxide Reductases. J. Biol. Chem.
279: 30210-30218
[Abstract]
[Full Text]
-
Ross, P. J., Lavelle, E. C., Mills, K. H. G., Boyd, A. P.
(2004). Adenylate Cyclase Toxin from Bordetella pertussis Synergizes with Lipopolysaccharide To Promote Innate Interleukin-10 Production and Enhances the Induction of Th2 and Regulatory T Cells. Infect. Immun.
72: 1568-1579
[Abstract]
[Full Text]
-
Liu, M., Gingery, M., Doulatov, S. R., Liu, Y., Hodes, A., Baker, S., Davis, P., Simmonds, M., Churcher, C., Mungall, K., Quail, M. A., Preston, A., Harvill, E. T., Maskell, D. J., Eiserling, F. A., Parkhill, J., Miller, J. F.
(2004). Genomic and Genetic Analysis of Bordetella Bacteriophages Encoding Reverse Transcriptase-Mediated Tropism-Switching Cassettes. J. Bacteriol.
186: 1503-1517
[Abstract]
[Full Text]
-
Carbonetti, N. H., Artamonova, G. V., Mays, R. M., Worthington, Z. E. V.
(2003). Pertussis Toxin Plays an Early Role in Respiratory Tract Colonization by Bordetella pertussis. Infect. Immun.
71: 6358-6366
[Abstract]
[Full Text]
-
El-Azami-El-Idrissi, M., Bauche, C., Loucka, J., Osicka, R., Sebo, P., Ladant, D., Leclerc, C.
(2003). Interaction of Bordetella pertussis Adenylate Cyclase with CD11b/CD18: ROLE OF TOXIN ACYLATION AND IDENTIFICATION OF THE MAIN INTEGRIN INTERACTION DOMAIN. J. Biol. Chem.
278: 38514-38521
[Abstract]
[Full Text]
-
Burns, V. C., Pishko, E. J., Preston, A., Maskell, D. J., Harvill, E. T.
(2003). Role of Bordetella O Antigen in Respiratory Tract Infection. Infect. Immun.
71: 86-94
[Abstract]
[Full Text]
-
Heininger, U., Cotter, P. A., Fescemyer, H. W., Martinez de Tejada, G., Yuk, M. H., Miller, J. F., Harvill, E. T.
(2002). Comparative Phenotypic Analysis of the Bordetella parapertussis Isolate Chosen for Genomic Sequencing. Infect. Immun.
70: 3777-3784
[Abstract]
[Full Text]
-
Sisti, F., Fernandez, J., Rodriguez, M. E., Lagares, A., Guiso, N., Hozbor, D. F.
(2002). In Vitro and In Vivo Characterization of a Bordetella bronchiseptica Mutant Strain with a Deep Rough Lipopolysaccharide Structure. Infect. Immun.
70: 1791-1798
[Abstract]
[Full Text]
-
Guermonprez, P., Khelef, N., Blouin, E., Rieu, P., Ricciardi-Castagnoli, P., Guiso, N., Ladant, D., Leclerc, C.
(2001). The Adenylate Cyclase Toxin of Bordetella pertussis Binds to Target Cells via the {alpha}M{beta}2 Integrin (Cd11b/Cd18). JEM
193: 1035-1044
[Abstract]
[Full Text]
-
Register, K. B., Ducey, T. F., Brockmeier, S. L., Dyer, D. W.
(2001). Reduced Virulence of a Bordetella bronchiseptica Siderophore Mutant in Neonatal Swine. Infect. Immun.
69: 2137-2143
[Abstract]
[Full Text]
-
Harvill, E. T., Preston, A., Cotter, P. A., Allen, A. G., Maskell, D. J., Miller, J. F.
(2000). Multiple Roles for Bordetella Lipopolysaccharide Molecules during Respiratory Tract Infection. Infect. Immun.
68: 6720-6728
[Abstract]
[Full Text]
-
Weingart, C. L., Mobberley-Schuman, P. S., Hewlett, E. L., Gray, M. C., Weiss, A. A.
(2000). Neutralizing Antibodies to Adenylate Cyclase Toxin Promote Phagocytosis of Bordetella pertussis by Human Neutrophils. Infect. Immun.
68: 7152-7155
[Abstract]
[Full Text]
-
Forde, C. B., Shi, X., Li, J., Roberts, M.
(1999). Bordetella bronchiseptica-Mediated Cytotoxicity to Macrophages Is Dependent on bvg-Regulated Factors, Including Pertactin. Infect. Immun.
67: 5972-5978
[Abstract]
[Full Text]
-
Harvill, E. T., Cotter, P. A., Miller, J. F.
(1999). Pregenomic Comparative Analysis between Bordetella bronchiseptica RB50 and Bordetella pertussis Tohama I in Murine Models of Respiratory Tract Infection. Infect. Immun.
67: 6109-6118
[Abstract]
[Full Text]